Asciminib with chemotherapy for young people with relapsed Philadelphia-positive acute lymphoblastic leukemia
Tests asciminib in young people whose acute lymphoblastic leukemia returned or resisted treatment.
Key facts
- Who runs it
- Novartis Pharmaceuticals
- Where
- Seoul, South KoreaSee the siteAlso in 5 other countries, 7 sites
- Trial code
- Registry title
- Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 50 people, planned
- Started
- 5 Jul 2026
- Expected to end
- 30 May 2036
- Type of study
- Interventional
- Treatments tested
- Asciminib Adult formulation
- Asciminib Pediatric formulation
- Dexamethasone
- Vincristine
- Blinatumomab
- Methotrexate (intrathecal)
- Cytarabine (intrathecal)
- Hydrocortisone (intrathecal)
- Prednisolone (intrathecal)
- Record updated
- 12 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young adults aged 1 to 30 years whose acute lymphoblastic leukemia (ALL) has come back or did not respond to treatment. The leukemia must be Philadelphia-positive or ABL-class Ph-like.
- Age
- From 1 year to 30 years old.
- Sex
- All sexes can join.
- Disease stage
- Relapsed or refractory B-cell ALL that is Ph+ or ABL1/ABL2 fusion Ph-like, with active disease (more than 0.01% leukemia cells) in the bone marrow. The leukemia must have been shown to carry CD19.
- Earlier treatment
- People with relapsed disease must have had at least one line of therapy. If they had anti-CD19 therapy (such as CD19 CAR T cells or blinatumomab), CD19 must be shown again afterwards.
- Biomarker or test result
- Ph+ ALL or ABL1 or ABL2 fusion Ph-like ALL. People with the ABL1 T315I mutation can join.
Main reasons for not taking part
- More than 3 relapses of ALL
- Disease outside the bone marrow (non-CNS and/or isolated CNS disease)
- CNS3c disease (clinical signs of leukemia in the central nervous system)
- Heart rhythm problems or other significant heart disease
- Severe or uncontrolled other medical disease
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Evidence of Ph+ ALL or ABL1 or ABL2 fusion Ph-like ALL, inclusive of participants with ABL1 T315I mutation
- Participants with CNS1, CNS2, CNS3a, or CNS3b at screening
- Active B-Cell ALL at screening defined by MFC or IG/TCR PCR of ALL blasts >0.01% in participants with either:; Primary refractory disease (>0.01% ALL blasts present at the end of consolidation) OR; Relapsed ALL with evidence of involvement of BM with ALL (MFC or IG/TCR PCR >0.01%) after at least one line of therapy
- Documented history of CD19 expressing B-cell ALL (in peripheral blood or bone marrow by flow cytometry); For participants who received anti-CD19 targeted therapy (e.g CD19 CAR T cells or blinatumomab), CD19 expressing B-cell ALL must be documented after anti-CD19 therapy completion prior to cycle 1 day 1
- Adequate hepatic and renal function (local laboratory analysis) as defined:; ALT ≤ 5x upper limit of normal (ULN) for age; Total bilirubin (sum of conjugated + unconjugated) ≤ 1.5 x ULN) for age, except for participants with Gilbert's syndrome who may only be included if total bilirubin ≤ 3.0 x ULN or direct bilirubin ≤ 1.5 x ULN; Estimated glomerular filtration rate (eGFR) using the Cockcroft-Gault formula in participants ≥ 18 years, OR radioisotope GFR ≥50 mL/min/1.73 m\^2, OR creatinine based on age and sex for participants < 18 years old
- Adequate cardiac function defined as shortening fraction ≥27% by echocardiogram (ECHO) OR left ventricular ejection fraction of ≥50% by ECHO
Who cannot take part
- Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol; Other protocol defined inclusion/exclusion criteria may apply
- Extramedullary disease (non-CNS and/or isolated CNS disease)
- Participants with CNS3c (Clinical signs of CNS leukemia (such as facial nerve palsy, brain/eye involvement or hypothalamic syndrome))
- Cardiac or cardiac repolarization abnormality, including but not limited to clinically significant cardiac arrhythmias, long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome or other clinically significant heart disease (e.g., congestive heart failure, etc.)
- Participants with >3 relapses of ALL
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 30 years old?
Where in South Korea
Also in 5 other countries, 7 sites
- Seoul, KoreaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
About the trial
What the trial wants to find out
Multi-center, open-label, single arm study of asciminib in participants aged ≥1 year to ≤30 years old with r/r Ph+ or ABL-class Ph-like ALL. This study will have 2 parts: Part 1 dose escalation and Part 2 dose expansion. Part 1 dose escalation will enroll participants aged ≥1 year to ≤30 years to determine the recommended phase 2 dose (RP2D) of asciminib when administered with low intensity chemotherapy. Part 2 dose expansion will enroll participants aged ≥1 year to ≤30 years to evaluate safety, tolerability, and efficacy of asciminib at the RP2D with the treatment regimen.
The group in the trial
- Single ArmTreatment being tested
Asciminib Adult formulation group: escalating doses evaluated Asciminib Pediatric formulation group: dose is based on body weight; dose level being evaluated will be converted into a mg/kg daily dose. For known T315I mutation: Fixed asciminib dose twice daily or the pediatric formulation dose equivalent twice daily.
Treatment: Asciminib Adult formulation, Asciminib Pediatric formulation, Dexamethasone, Vincristine, Blinatumomab, Methotrexate (intrathecal), Cytarabine (intrathecal), Hydrocortisone (intrathecal), and Prednisolone (intrathecal)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Open-label, Phase I/II Study to Evaluate Safety and Efficacy of Asciminib With Chemotherapy Followed by Asciminib Plus Blinatumomab in Pediatric, Adolescent, and Young Adults With Relapsed or Refractory BCR::ABL1-positive (Philadelphia Positive, Ph+) or BCR::ABL1-like (Ph-like) ALL
- Plain-language title
- Asciminib with chemotherapy for young people with relapsed Philadelphia-positive acute lymphoblastic leukemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT07387926, who can take part
- Record updated
- 12 November 2026